Background: Reactive oxygen-derived species, including those generated during myocardial ischemia and reperfusion induced by cardioplegia, have been suggested to be involved in myocardial apoptosis induction. The purpose of our study was to investigate (1) whether cardioplegic arrest initiates apoptosis in the hearts of cardiac surgery patients and (2) whether reactive oxygen-derived species scavenging with N-acetylcysteine attenuates myocardial apoptosis initiation.
A poptosis has been shown to be involved in various cardiac pathologies, including heart failure, cardiomyopathy, myocarditis, and myocardial ischemia/reperfusion. [1] [2] [3] Apoptosis can be triggered through different mechanisms in response to both intracellular and extracellular signals. 4, 5 For example, cytokine release by macrophages and myocytes can activate the apoptosis signal cascade. 6 In addition, reactive oxygen-derived species (ROS), often called oxidative stress, have been shown to induce apoptosis in cardiac myocytes subjected to ischemia and reperfusion. 7, 8 Accordingly, we and other researchers have recently demonstrated that cardioplegia-induced ischemia and reperfusion is associated with apoptosis initiation in adult porcine, 9 canine, 10 and rat 11 and neonatal lamb left ventricular (LV) myocytes, 12 as well as human atrial myocytes. 13 Because cardiac apoptosis has been suggested to be involved in postoperative myocardial stunning, 13 cardiac apoptosis prevention could represent an attractive adjunct to current myocardial protection techniques in cardiac surgery. One potential apoptosis prevention strategy could be ROS scavenging. Experimentally, Dobsak and colleagues 11 have recently shown that ROS scavenging with the iron chelator deferoxamine resulted in fewer apoptotic myocytes associated with better functional recovery in rat hearts after 4 hours of cardioplegic arrest. We have recently demonstrated that the antioxidant and ROS scavenger N-acetylcysteine (NAC) prevented direct ROS-mediated myocardial alterations in the LV myocardium of patients subjected to cardioplegia 14 ; however, whether NAC attenuates cardiac apoptosis initiation has not been investigated.
Therefore, the purpose of our study was to compare the effects of NAC versus placebo on activation of caspases-3 and -7, the apoptosis signal pathway central effector enzymes, in LV myocardium of patients subjected to coronary artery operation during cardioplegic arrest.
Materials and Methods
After approval by the University of Cologne Human Ethics Committee, written, informed consent was obtained from each patient during the preoperative interview. We used LV biopsy specimens from our previous study, 14 in which we randomized 40 patients (9 women and 31 men) scheduled for elective or urgent coronary artery bypass surgery into either the NAC group (n ϭ 20) or the placebo group (n ϭ 20) according to a computer-generated allocation list. Patients' biometric data and procedures are given in Tables 1 and 2 according to reference. 14 Briefly, patients of the NAC group received 100 mg of NAC per kilogram body weight into the cardiopulmonary bypass (CPB) prime followed by intravenous infusion at 20 mg of NAC per kilogram of body weight per hour until the end of CPB; patients in the placebo group received equivalent amounts of placebo. Patients were subjected to CPB at 32°C to 34°C, the aorta was crossclamped, and myocardial revascularization was performed during cardioplegic arrest by using single-shot antegrade cold (4°C) crystalloid Bretschneider cardioplegia (Custodiol; Dr Köhler Chemie, Alsbach, Germany).
LV Biopsies
Before CPB initiation, we collected a transmural biopsy sample from a fat-free area of the LV anterior wall by using a 14-gauge biopsy needle (Gallini, Modena, Italy). A second LV biopsy sample was taken at the end of the extracorporeal circulation before weaning from CPB. All LV biopsy samples were placed in 4% paraformaldehyde for 4 hours and then rinsed in 0.1 mol/L phosphate-buffered saline (PBS) for 24 hours, followed by storage for 12 hours in PBS solution with 18% sucrose for cryoprotection. Finally, they were frozen at Ϫ80°C. Because of the small size of the LV biopsy samples, we were able to densitometrically quantitate cardiac myocyte staining for active caspase-3 (before CPB and at the end of CPB) in 18 patients of the placebo group and 18 patients of the NAC group and for active caspase-7 in 17 patients of the placebo group and 17 patients of the NAC group.
Immunocytochemistry
Before immunohistochemical examination, 7-m slices from the biopsy samples were placed in a bathing solution of 3% H 2 O 2 and methanol for 20 minutes, and then cells were lysed with 0.25% Triton X-100 (Rohm & Haas Co, Philadelphia, Pa) in ammonium chloride 0.5 mol/L. Thereafter, specimens were treated with 5% bovine serum albumin solution in Tris-buffered saline (TBS) 0.05 mol/L. Before each step, the sections were rinsed 3 times in TBS buffer 0.05 mol/L. Incubation with primary rabbit anti-active caspase-3 antibody (1:500; Pharmingen, San Diego, Calif) and rabbit anti-active caspase-7 antibody (1:500; Biocat, Heidelberg, Germany) were performed in a TBS-based solution of 0.8% bovine serum albumin and NaN 3 20 mmol/L for 12 hours at 4°C. After rinsing with TBS, the sections were incubated with the corresponding secondary biotinylated goat anti-rabbit antibody (1:400; DAKO, Hamburg, Germany) for 1 hour at room temperature. A streptavidin-horseradish-peroxidase complex was then applied as a detection system (1:150) for 1 hour. Finally, staining was developed for 10 to 20 minutes with 3,3-diaminobenzidine tetrahydrochloride in PBS 0.1 mol/L.
Active Caspase-3 and Caspase-7 Television Densitometry
All LV biopsy slices were incubated and stored under identical conditions. For quantitative intensity analyses of active caspase-3 and -7 immunostaining in cardiac myocytes, we measured the gray values of 30 cardiac myocytes from 6 randomly selected areas. The staining intensity was reported as the mean measured cardiac 
FAC, fractional area of contraction as determined by transesophageal echocardiography before cardiopulmonary bypass.
Reasons for missing values (n Ͻ 20) are *not determined at the time of heart catheter insertion; †catheter placement impossible; and ‡trans-esophageal echocardiography not performed.
myocyte gray value minus the background gray value. The background gray value was measured at a cell-free area of the slice. For staining intensity detection, a Zeiss (Jena, Germany) Axiophot microscope coupled to a 3-chip charge-coupled device camera was used, and analysis was performed by using the Optimas 6.01 image-analysis program (Optimas 6.01, Media Cybernetics, Silver Spring, Md) installed on a personal computer.
Statistical Analysis
Continuous variables were summarized as mean Ϯ SD. Changes in outcome variables were analyzed for statistical significance at a level of ␣ ϭ 5% by using 2-tailed Student t tests for unpaired or paired samples, where appropriate. Corresponding 95% confidence intervals (CI) are given to allow assessment of effect sizes for clinical relevance. Statistical analyses were performed with the software package SPSS for Windows, release 10.0.7 (SPSS Inc, Chicago, Ill). The P values reported were not adjusted for multiple testing.
Results
Cardiac myocyte immunostaining for active caspases-3 and -7 is depicted in Figure 1 . Compared with before CPB, LV cardiac myocytes of the placebo group demonstrated caspase-3 and -7 activation at the end of CPB. In contrast, cardiac myocytes of the NAC group remained negative for both caspases at the end of CPB. In the placebo group, caspase-3 staining increased from 11.6 Ϯ 2.4 gray units before CPB to 18.7 Ϯ 8.0 gray units at the end of CPB (P ϭ .0017; 95% CI for mean change, 3.4 to 10.9), and caspase-7 staining increased from 23.8 Ϯ 11.2 gray units before CPB to 28.9 Ϯ 12.0 gray units at the end of CPB (P ϭ .0019; 95% CI for mean change, 2.4 to 7.8). In the NAC group, caspase-3 staining decreased from 14.9 Ϯ 3.4 gray units before CPB to 11.7 Ϯ 2.6 gray units at end of CPB (P ϭ .009; 95% CI for mean change, Ϫ1.1 to Ϫ5.2), and caspase-7 staining decreased from 25.8 Ϯ 11.0 gray units before CPB to 20.8 Ϯ 11.3 gray units at the end of CPB (P ϭ .003; 95% CI for mean change, Ϫ2.2 to Ϫ8.0). The changes (from before CPB to the end of CPB) in cardiac myocyte density for caspases-3 and -7 are depicted in Figure 2 . Patients' biometrics, intraoperative procedures, and clinical outcomes were similar between groups; there were no deaths or perioperative myocardial infarctions 14 (Tables 1  and 2 ). We did not observe adverse effects attributable to NAC. Post-CPB hemodynamics, including heart rate, vas- (Tables 1 and 2 ). We did not find differences among the degree of caspase staining and arterial hypertension, diabetes mellitus, LV ejection fraction, or LV end-diastolic pressure (P Ͼ .27).
Discussion
Our data show that NAC prevents cardioplegia-induced apoptosis signal cascade initiation in human LV myocardium, because both cardiac myocyte caspase-3 and caspase-7 activities were significantly lower in patients who received NAC compared with placebo. Together with our clinical trial, which demonstrated that NAC protected the CSP myocardium from direct ROS-mediated alterations such as 8-iso-prostaglandin-F 2 ␣ and nitrotyrosine formation, 14 these data show for the first time that ROS scavenging can effectively attenuate cardiac myocyte apoptosis induction in patients who undergo cardioplegia. Apoptosis is a genetically programmed process for the death and subsequent removal of injured cells. Several extracellular and intracellular stimuli, including cytokine release, mechanical stretch, and oxidative stress, can trigger the apoptosis signal cascade. [4] [5] [6] The apoptosis execution phase is initiated by cleavage and, thus, activation of downstream or effector caspases such as caspases-3 and -7. 4, 5 Subsequently, these activated caspases can cleave genomic DNA, leading to DNA fragmentation and, ultimately, apoptotic cell death. 4, 5 Even though the clinical relevance of cardioplegia-induced apoptosis is not yet well established, recent work suggests that apoptosis is initiated by cardioplegic arrest in diseased adult hearts and may contribute to postoperative myocardial stunning. 13 It has to be noted, however, that detection of cleaved caspases as performed in this study does not necessarily indicate substrate cleavage by activated caspases, because inhibitory proteins may block cleaved caspases. In fact, this inhibition of the apoptosis signal cascade explains the unchanged post-CPB cardiac function without signs of massive apoptotic cardiac cell loss despite the homogeneous myocardial apoptosis initiation induced by cardioplegia and reperfusion. However, considering the potential long-term effects attributable to apoptosis initiation, including mitochondrial alterations, functional and structural protein derangement, and accelerated cell aging, 4, 5, 15 apoptosis prevention has to be regarded as a cardioprotective measure.
Because ROS can trigger apoptosis 4, 5, [7] [8] [9] and because cardioplegia-induced myocardial ischemia/reperfusion is associated with massive ROS production, 16 ROS scavenging may attenuate apoptosis induction in hearts exposed to cardioplegia. Experimentally, effective apoptosis prevention by ROS scavenging with the glutathione peroxidase mimic ebselen has been demonstrated in a clinically relevant pig model of regional myocardial ischemia and cardioplegic arrest. 17 In addition, ROS scavenging with the iron chelator deferoxamine resulted in fewer apoptotic myocytes and better functional recovery in rat hearts after 4 hours of cardioplegic arrest. 11 In this study, we found that the antioxidant and reduced glutathione precursor NAC prevented the activation of caspases-3 and -7 in the LV myocytes of patients subjected to cardioplegia. In contrast, the hearts of patients in the placebo group demonstrated significant caspase-3 and -7 activation, indicating apoptosis signal cascade initiation. Although the early postoperative hemodynamics and short-term clinical outcome were not different between the NAC and placebo groups, 14 these data suggest that ROS scavenging with NAC may be a useful adjunct to myocardial protection strategies. It is interesting that we found that in the NAC group, cardiac myocyte caspase-3 and -7 activities actually decreased from before CPB to the end of CPB, indicating apoptosis signal cascade activation during the period of anesthesia induction, thoracotomy, and cannulation for CPB. Because previous work showed myocardial 8-isoprostaglandin-F 2 ␣ and nitrotyrosine formation before CPB, 16 some ROS must have been induced by anesthesia induction, surgical trauma, or a combination thereof. Thus, to yield the full potential benefit of its ROS-scavenging properties, NAC application should start before anesthesia induction.
In conclusion, our data show for the first time that cardioplegia-induced apoptosis signal cascade activation in human LV cardiac myocytes can effectively be prevented by ROS scavenging with NAC. However, the data of our study do not allow us to determine how many cardiac myocytes, if any, completed the apoptosis signal cascade in hearts not protected by NAC, because apoptosis completion probably requires several hours 18 and, thus, cannot be detected within the time frame of routine coronary artery surgery. Despite this lack of evidence for apoptosis completion, caspase activity may still have a significant effect on myocardial function. As shown by Ricci and colleagues, 19 caspase-3 cleavage is also associated with functional deficits of complex I and complex II in the electron transport chain when the outer mitochondrial membrane has been permeabilized, as occurs upstream of caspase activation. Therefore, caspase activation inhibition seems to be beneficial even before apoptosis is completed. Future studies are required to further elucidate the clinical relevance of Figure 2 . Change from before CPB to the end of CPB in cardiac myocyte density for active caspases-3 and -7 in both groups (data are mean ؎ SD; for caspase-3, n ‫؍‬ 18 in the placebo group; n ‫؍‬ 18 in the N-acetylcysteine group; for caspase-7, n ‫؍‬ 17 in the placebo group; n ‫؍‬ 17 in the N-acetylcysteine group).
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